Brought to you by 
Roche signs on for rights to Plexxikon's PLX4032 cancer agent
03 Dec 2015
Executive Summary
Plexxikon (uses Scaffold-Based Drug Discovery technology for structural screening and analysis of small molecules) has licensed Roche exclusive worldwide development and marketing rights to PLX4032 for cancer.
Deal Industry
- Pharmaceuticals
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
- Pharmacogenetics-Pharmacogenomics
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com